AC Immune SA Common Stock ACIU
i
Market datapartial · fetched 2026-11-11T04:22:04.522Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-05-21
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T00:34:49.798505417Z
FundamentalsAlpha Vantage · unavailable
AC Immune SA Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.90 | 323.1% | 66.5% | |||
| 25Δ | 3.09 | 302.7% | 60.7% | |||
| 30Δ | 3.28 | 282.4% | 54.9% | |||
| 35Δ | 3.47 | 262.1% | 49.2% | |||
| 40Δ | 3.66 | 241.7% | 43.4% | |||
| 45Δ | 3.85 | 221.4% | 37.6% | |||
| 50Δ | 4.04 | 201.1% | 31.9% | |||
| 55Δ | 4.23 | 180.7% | 26.1% | |||
| 60Δ | 4.43 | 160.4% | 20.3% | |||
| 65Δ | 4.62 | 140.1% | 14.6% | |||
| 70Δ | 4.81 | 119.7% | 8.8% | |||
| 75Δ | 5.00 | 99.4% | 3.1% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.90
- IV
- 323.1%
- B/E move
- 66.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.09
- IV
- 302.7%
- B/E move
- 60.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.28
- IV
- 282.4%
- B/E move
- 54.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.47
- IV
- 262.1%
- B/E move
- 49.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.66
- IV
- 241.7%
- B/E move
- 43.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.85
- IV
- 221.4%
- B/E move
- 37.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.04
- IV
- 201.1%
- B/E move
- 31.9%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.23
- IV
- 180.7%
- B/E move
- 26.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.43
- IV
- 160.4%
- B/E move
- 20.3%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.62
- IV
- 140.1%
- B/E move
- 14.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.81
- IV
- 119.7%
- B/E move
- 8.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.00
- IV
- 99.4%
- B/E move
- 3.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 172.68% |
Biotechnology
ACOG
Description unavailable
More →ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with…
More →ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and…
More →AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in…
More →AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The…
More →AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →